Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 CFR Part 26—Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Community
21 CFR Part 26—Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Community, “Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit…”, is a CFR part of 21 CFR Chapter I, Subchapter A—GENERAL; it is made under 34 laws; in force.
https://ontology.bommaritollc.com/id/01a0f094-b7ef-7601-a5d1-ac01dec9bdba
Elsewhere
Facts
| adms:identifier | |
| authority note | 5 U.S.C. 552; 15 U.S.C. 1453, 1454, 1455; 18 U.S.C. 1905; 21 U.S.C. 321, 331, 351, 352, 355, 360, 360b, 360c, 360d, 360e, 360f, 360g, 360h, 360i, 360j, 360l, 360m, 371, 374, 381, 382, 383, 393; 42 U.S.C. 216, 241, 242l, 262, 264, 265.en |
| eli:based_on | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 CFR Part 26 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Communityen |
| schema:url | |
| skos:prefLabel | 21 CFR Part 26—Mutual recognition of pharmaceutical good manufacturing practice reports, medical device quality system audit reports, and certain medical device product evaluation reports: United States and the European Communityen |
| source note | 63 FR 60141, Nov. 6, 1998, unless otherwise noted.en |
Related
Cited by (20)eli:cites
- 21 CFR 26.0 General.
- 21 CFR 26.47 Role and composition of the Joint Sectoral Committee.
- 21 CFR 26.61 Purpose of this part.
- 21 CFR 26.62 General obligations.
- 21 CFR 26.63 General coverage of this part.
- 21 CFR 26.64 Transitional arrangements.
- 21 CFR 26.65 Designating authorities.
- 21 CFR 26.66 Designation and listing procedures.
- 21 CFR 26.67 Suspension of listed conformity assessment bodies.
- 21 CFR 26.68 Withdrawal of listed conformity assessment bodies.
- 21 CFR 26.69 Monitoring of conformity assessment bodies.
- 21 CFR 26.70 Conformity assessment bodies.
- 21 CFR 26.71 Exchange of information.
- 21 CFR 26.72 Sectoral contact points.
- 21 CFR 26.74 Preservation of regulatory authority.
- 21 CFR 26.75 Suspension of recognition obligations.
- 21 CFR 26.81 Final provisions.
- 21 CFR Appendix D to Subpart A of Part 26 Criteria for Assessing Equivalence for Post- and Preapproval
- 21 CFR Appendix E to Subpart A of Part 26 Elements To Be Considered in Developing a Two-Way Alert System
- FR Doc. 2024-21559: Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community
Parts (4)schema:isPartOf
- 21 CFR 26.0 General.
- 21 CFR Part 26, Subpart A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices
- 21 CFR Part 26, Subpart B—Specific Sector Provisions for Medical Devices
- 21 CFR Part 26, Subpart C—“Framework” Provisions